Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Mycophenolic Acid for CMV Prevention in Kidney Transplant Recipients
NCT02328963Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- May 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in cytomegalovirus infection (CMV) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Number of participants without CMV infection and without graft loss in CMV seropositive kidney transplant recipients at 6 months. Started May 2014; status: completed.
02
Drugs
everolimus
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02328963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328963.